The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma
- 15 September 1999
- Vol. 86 (6) , 957-968
- https://doi.org/10.1002/(sici)1097-0142(19990915)86:6<957::aid-cncr10>3.0.co;2-8
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myelomaCancer, 1997
- A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment GroupEuropean Journal Of Cancer, 1995
- An Aggressive High Dose Cyclophosphamide and Prednisone Regimen for Advanced Multiple MyelomaLeukemia & Lymphoma, 1994
- Treatment of multiple myeloma with interferon alpha: the Scandinavian experienceBritish Journal of Haematology, 1991
- Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction ChemotherapyNew England Journal of Medicine, 1990
- Interferon in the Treatment of Refractory Multiple Myeloma: An Eastern Cooperative Oncology Group StudyLeukemia & Lymphoma, 1990
- Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trialEuropean Journal of Cancer and Clinical Oncology, 1986
- High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myelomaCancer, 1984
- The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute LeukemiaNew England Journal of Medicine, 1979
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958